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ABSTRACT
MicroRNAs (miRNAs) are small noncoding single stranded RNAs that are
considered master regulators of gene expression. They are also an emerging class
of therapeutic agents with significant potential for the prevention and treatment of
many diseases, including cancer. Many different forms of cancer are associated
with loss or reduced accumulation of one or more miRNAs that function as tumor
suppressors. In animal models, restoration of missing tumor suppressor miRNAs
prevents the initiation, progression and/or spread of the disease. However, the
current absence of an efficient method for delivery of therapeutic miRNAs is a
critical barrier to their use.

The research in this thesis has tested a novel

chemopreventive strategy for miRNA replacement therapy based on ingestion of
plant matter that has been bioengineered to produce mammalian tumor
suppressor miRNAs. The work builds on the Vance lab’s promising pilot study
showing that oral administration of plant RNA spiked with a cocktail of three tumorsuppressor miRNAs (miR-34a, -143, and -145), synthesized with the 3’methylation characteristic of plant miRNAs, has significant chemopreventive
activity in the ApcMin/+ mouse, a well-established animal model of colon cancer.
Based on this work, Arabidopsis thaliana was bioengineered to produce the same
three tumor suppressor miRNAs used in the earlier study. This required devising
strategies to engineer miRNAs that are not the standard 21 nt size of most plant
miRNAs. In a small pilot study using these
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plant-made tumor suppressor miRNAs, we found that ApcMin/+ mice that were fed
a diet containing the transgenic Arabidopsis tissue developed significantly fewer
tumors than mice fed a control diet that was calorically and nutritionally matched,
but did not contain plant tissue. Although the results using this delivery method
were promising, the approach was limited experimentally due to the low
concentration of the miRNAs in lyophilized tissues as well as the feeding
preferences of the mice. Thus, subsequent work focused on a strategy to deliver
high levels of plant-made miRNAs by packaging them into plant exosome-like
vesicles, which are taken up by the mammalian digestive tract after ingestion. For
plant exosome-like vesicles to be effective in future studies, techniques for
enhancing the loading of bioengineered miRNAs were developed. Work reported
here points to the importance of the identity of the 5’ nucleotide of the engineered
miRNA for efficient loading into plant exosome-like vesicles for subsequent
delivery by ingestion.
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CHAPTER 1
INTRODUCTION
1.1 MICRORNAS
microRNAs (miRNAs) are small noncoding single stranded RNAs that are
considered master regulators of gene expression (Carthew, Richard W. and
Sontheimer 2009). These small noncoding RNAs are a highly conserved part of
an ancient pathway of gene regulation that exists in nearly all eukaryotic organisms
(Cai et al. 2009). They incorporate into a protein complex called the RNA-induced
silencing complex (RISC), in which the miRNA acts as a guide to target specific
messenger RNAs (mRNAs) using the base pairing rules (Schanen and Li 2011).
Once RISC and its attached miRNA are bound to a target mRNA, translation is
blocked either directly or by mRNA degradation (Fabian et al. 2009). Because a
single miRNA can potentially have hundreds of targets, this method of gene
regulation is both complex and highly versatile (Graves and Zeng 2012).

1.2 ROLE OF MIRNA DYSREGULATION IN DISEASE
MiRNAs control many cellular processes, ranging from metabolism to
cellular proliferation and differentiation. When the normal balance of miRNAs is
disrupted, it can lead to a wide variety of human diseases, including many forms
of cancer (Jansson and Lund 2012). Because miRNAs are both highly specific
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and effective gene regulators, their potential as therapeutic agents is now widely
recognized (van Rooij and Kauppinen 2014). It has been shown in both animal
models and tissue culture cells that if therapeutic miRNAs can be introduced to
diseased tissue, many diseases can be inhibited, blocked, or even regressed
(Bader, Brown, and Winkler 2010). Although miRNAs are a promising therapeutic
agent, development of methods to deliver small RNAs is a challenging problem
that has been the focus of much research (Hellman and Fried 2009). Current
strategies involve chemically altering miRNAs or using nanoparticles to increase
both stability and uptake (Bader et al. 2011). These delivery techniques are not
only expensive, they may also introduce toxicity and reduce the effectiveness of
the miRNAs.

1.3 CROSS KINGDOM GENE REGULATION BETWEEN PLANTS AND ANIMALS
Recently, the existence of cross kingdom gene regulation between plants
and animals via ingestion of plant tissues was reported (Zhang et al., 2012). This
discovery was made when endogenous plant miRNAs were found in mammals
and shown to be functional to regulate expression of mammalian genes (Zhang et
al., 2012). This ground-breaking publication presented evidence that endogenous
plant miR168a, an abundant rice miRNA, was absorbed by the mammalian GI
tract. The only possible source of this plant miRNA was from the animal’s diet.
miR168a was found in several tissues, including the heart, spleen, lung, kidney,
stomach, small intestine, and brain, and it was found to target low-density
lipoprotein receptor adapter protein 1 (LDLRAP1), a protein that influences LDL
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uptake in the blood. Since this discovery, several other labs have found many
more plant miRNAs regulating genes in mammals, reinforcing the existence of this
pathway (Pirŕ et al., 2016; Yang et al., 2016; Chin et al., 2016; Yang et al., 2015;
Pastrello et al., 2016; Zhou et al., 2014).

1.4 PLANTS TO PRODUCE AND DELIVERY TUMOR SUPPRESSOR MIRNAS
Because plants can be genetically engineered to produce miRNAs of any
desired sequence, cross kingdom regulation by ingested plant miRNAs raised the
possibility of using edible plants to produce therapeutic mammalian miRNAs that
could be delivered via the diet to prevent or treat disease (Hirschi et al., 2015;
Mlotshwa et al., 2015). Previous work from our lab tested this idea by feeding a
daily dose of plant RNA spiked with a cocktail of mammalian tumor suppressor
miRNAs (miR-34a, miR-143, miR-145) to ApcMin/+ mice, a model for colon cancer.
This treatment resulted in a highly statistically significant reduction in tumor burden
in mice receiving the tumor suppressor miRNAs compared to controls (Mlotshwa
et al. 2015). The miRNAs used in this study were not made in a plant, but
synthetically made with a 2′-O-methylation at their 3′ termini, a major characteristic
of plant miRNAs, and meant to mimic miRNA produced in the plant.

In this

dissertation, this hypothesis is tested further, by establishing methods of
bioengineering plants to produce mammalian tumor suppressor miRNAs, assaying
their chemopreventive activity by feeding them to ApcMin/+ mice, and characterizing
the loading of miRNAs into plant exosome-like vesicles (EVs) for use as an efficient
delivery vehicle.
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CHAPTER 2
DESIGN OF MIRNA CONSTRUCTS AND GENERATION OF
TRANSGENIC LINES
2.1 INTRODUCTION
2.1.1 USING PLANTS AS BIOFACTORIES TO PRODUCE THERAPEUTIC MIRNAS
The Vance lab pilot study showed that oral administration of plant RNA
spiked with a cocktail of three mammalian tumor-suppressor miRNAs (miR-34a,
miR-143, and miR-145), synthesized with the 3’-methylation characteristic of plant
miRNAs, has significant chemopreventive activity in a mouse model of colon
cancer (Mlotshwa et al., 2015).

Based on this result, the first step in this

dissertation project was to use the model plant Arabidopsis thaliana to produce the
same three tumor suppressor miRNAs used in the earlier pilot study. Arabidopsis
was chosen as it is well characterized, easily transformed, and edible (Clough and
Bent, 1998). In addition, this technology has been patented by the Vance lab. The
technology to produce any miRNA in bioengineered plants is well-established,
simple, rapid and effective (Liang et al., 2012). The technique uses a natural plant
miRNA precursor gene as the starting structure and replaces the natural miRNA
sequence with the desired miRNA sequence, while also replacing the natural,
partially complementary miRNA* sequence to maintain the original secondary
stem-loop structure of the precursor. Maintaining this secondary structure ensures
4

proper processing of the miRNA by Dicer like-1 (DCL1), a ribonuclease protein
which functions in excising the mature miRNAs from the stem-loop (Werner et al.,
2010; Song et al., 2010). The engineered miRNA genes are then cloned under
the control of a strong constitutive promoter, the Cauliflower Mosaic Virus 35S
promoter (CaMV 35S), and stably introduced into plants using standard
transformation via Agrobacterium tumefaciens. Such engineered miRNAs are
essentially indistinguishable from endogenous plant miRNAs regarding both
biogenesis and function.

2.1.2 MAMMALIAN

TUMOR SUPPRESSOR MIRNAS MIR-34A, MIR-143, MIR-

145 AND THEIR ROLE IN CANCER
The three miRNAs chosen for these experiments are verified tumor
suppressor miRNAs, which have been shown to be down regulated in several
cancer types, including colon cancer (Gambari et al., 2016; Kano et al., 2010;
Clapé et al., 2009). If these three miRNAs are added back either in vivo or in vitro,
the disease can be prevented or progression can be inhibited, illustrating the
importance of these small RNAs in chemoprevention (Pramanik et al., 2011). The
miR-34a gene is a transcriptional target of the well-established tumor suppressor
protein p53, and is consequently down-regulated in many tumor types and paired
with several p53 downstream effects (Nalls et al., 2011). miR-143 and miR-145
are polycistronic, meaning they are expressed together on the same primary
transcript, and often work synergistically to knock down several shared oncogenic
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targets (Yan et al., 2014). Both of these miRNAs have been shown to positively
regulate their own expression by targeting negative regulators (Wang et al., 2015).

2.2 RESULTS AND DISCUSSION
2.2.1 DESIGN

APPROACHES FOR EXPRESSING MAMMALIAN THERAPEUTIC

MIRNAS LARGER THAN 21NT IN ARABIDOPSIS THALIANA

A common approach for expressing miRNAs in plants uses the miR319a
gene as backbone and replaces the natural miRNA sequence with the desired one.
However, this approach is designed to work for miRNAs that are 21 nucleotides
(nt) long, the length of the majority of plant miRNAs. This presented a problem
when designing constructs to produce mammalian miRNAs in plants because
mammalian miRNAs are often longer than 21 nt. Thus, it was necessary to
develop strategies to ensure the proper processing of miR-34a and miR-145,
which are 22 nt and 23 nt long, respectively. Two different approaches were used
and both approaches had success in producing an extremely high level of the
therapeutic miRNAs in Arabidopsis thaliana. miR-143 is a 21 nt miRNA; therefore,
no special modifications of the standard technique were needed to engineer this
miRNA.
The first design approach for making a miRNA longer than 21 nt involved
making modifications to the miRNA* region of the primary transcript. The stemloop secondary structure of primary miRNA transcripts in plants plays an important
role in recognition by DCL1 and proper processing to produce the mature miRNA.
Several mismatches are often found between the miRNA and miRNA* in the stem
6

loop structure, and maintenance of these mismatches is important in miRNA
processing. If the mismatches are altered, either by changing their location in the
stem loop or by altering them to complementary nucleotide pairs, it may disrupt
proper miRNA production.

The miR319a gene backbone has 3 mismatches

between the miRNA and miRNA*, found at nucleotides 1, 8, and 19 of the miRNA.
A published protocol for plants has shown that modifications can be made to the
miRNA* of a 21 nt miRNA that will result in production of a 22 nt miRNA rather
than the original 21 nt one (Song et al., 2010). The modification consists of
creating a deletion in the miRNA* sequence at the position of an existing mismatch
in the miRNA/miRNA* duplex. Although this modification makes a bulge in the
secondary structure, it does not adversely affect the processing function of DCL1.
Applying this approach, designs for generating the longer miR-34a and miR-145
miRNAs were made.
Due to the challenges in designing a miRNA over 21 nt long using the
miR319a gene backbone, a second strategy for generating mammalian miRNAs
in plants was also tried. This approach was to simply make a 21 nt version of the
mammalian miRNA by leaving off nucleotides from the 3’ end of the miRNA. This
is a valid approach because it has been reported that nucleotides lost from the 3’
end of the miRNA have little to no effect on targeting specificity of the miRNA
(Grimson et al., 2007). This is because specificity is primarily determined by the
miRNA seed sequence, a highly conserved region in mammalian miRNAs located
from nucleotides 2 – 7 of the 5’ end (Lewis et al., 2005). This approach was the
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one ultimately used to produce miR-34a, with one nucleotide being removed from
the 3’ end, thereby shortening the plant-produced version to 21 nt.

2.2.2 CLONING

MIRNA

CONSTRUCTS

AND

GENERATION

OF

TRANSGENIC

LINES
The engineered miR-143 21 nt and miR-34a 21 nt were designed using the
standard protocol, in which the plant miR319a gene is used as a backbone, with
the appropriate miR/miR* sequences replacing the original miR319a/miR319a*
sequences (Figure 2.1). The 23-nt miR-145 and the 22-nt version of miR-34a were
more complicated because of their length, and several different constructs were
evaluated in order to improve the chances of obtaining the correct sized miRNAs
These constructs had deletions made along their miRNA* region, but the only
construct that produced the correct size miRNA was miR-145 23nt that had 2
deletions at the 17 nt position of the miRNA (Figure 2.2; data not shown for some
constructs). Because the miR391a gene sequence is relatively short (406bp), the
appropriate complete DNA constructs were synthesized and cloned directly into
an entry vector (pENTR). To check for sequence accuracy, each miRNA construct
was sequenced.

Constructs with the correct sequences were used in a

recombination reaction to transfer the insert into an expression vector (pSITE-OA),
and subsequently sequenced again before transformation into Agrobacterium
tumefaciens, for transfer to plants.

Arabidopsis thaliana was transformed by

Agrobacterium-mediated transformation using the floral dip method (MartinezTrujillo et al., 2004).

Because the inserted DNA carries a specific antibiotic
8

resistance, the primary plant transformants (T1 generation) could then be selected
by plating seeds from the floral dip procedure onto media with the selective
antibiotic. Resistant seedlings (primary transformants) were transplanted into soil
for seed set, and the T2 generation seeds were plated again on selective media.
Transformants segregating 3:1 for antibiotic resistance were identified as putative
single insertion lines for further characterization. Seeds from these plants (T3
generation) were again selected for antibiotic resistance to identify homozygous
lines, which were then used to produce bulk seed (T4 generation) for the feeding
and exosome isolation experiments described in the next two chapters. RNA was
isolated from each of these homozygous lines, and expression levels of the
engineered miRNA was determined by RNA gel blot analysis using radioactive
probes specific for the small RNA. Homozygous plant lines expressing the highest
levels of each engineered miRNA of the correct size were used for the reported
experiments, and are also available for future studies.

2.2.3 CHARACTERIZATION OF PLANT-MADE MIR-34A, MIR-143 AND MIR-145
BY NORTHERN ANALYSIS AND NEXT GENERATION SEQUENCING

The population of miRNA size variants (isomiRs) for each of the tumor
suppressor miRNAs produced by transgenic plant lines, as well as that for the
endogenous plant miRNA miR319, was analyzed by next generation sequencing.
The relative abundance of endogenous plant miR319a small RNAs (64%) were
the reported 21nt sequence, with 27% a single nucleotide shorter (Figure 2.4A).
The two plant lines that were engineered to make a 21 nt miRNA (miR-143 and
9

the 21 nt version of miR-34a), like the endogenous miR319, both made high levels
of the desired 21 nt small RNA (45% and 49%, respectively), with the majority of
the remainder being a single nucleotide shorter (50% and 32%, respectively);
Figures 2.4B and C). Northern blot data showed that plants transformed with the
23 nt miR-145 constructs produced a ~23 nt miRNA at a high level in a stably
transformed homozygous Arabidopsis thaliana line. When examined by next
generation sequencing, the major variant was the desired size of 23 nt (57%), with
a population of 25 nt miRNA representing 27% of the size distribution (Figure
2.4D). None of the miR-34a lines designed to be 22 nt, however, produced a 22
nt miRNA at high level (Northern analysis; data not shown).
This work illustrates two approaches to produce exogenous miRNAs in
plants when the natural size of the miRNA is greater than 21 nt. Based on next
generation sequencing, it appears that both approaches result in a population of
small RNA isomiRs of slightly different sizes. Though all constructs produced a
population of size isomiRs, this is quite common in nature, as illustrated here by
the endogenous plant miR319a. The approach of designing a larger miRNA by
deleting nucleotides in the miRNA* appears to be successful in some cases (miR145), but not in others (miR-34a). The fall back approach, then, in the event that
the first approach is not successful, is to simply design a 21 nt version of the
desired miRNA by leaving off nucleotides from the 3’ end.
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Figure 2.1: miRNA/miRNA* region of miRNA
constructs. Shown are the miRNA/miRNA* sequences
(capital letters) for each of the miRNA constructs in the
miR319a backbone (A) endogenous miR319a miR/miR*
with mismatches at the 1 nt, 8 nt, 19 nt positions used as
a blueprint for mismatches in 21 nt constructs (B)
miR319a (C) miR-143 21 nt construct (D) miR-34a 21 nt
construct
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Figure 2.2: miRNA/miRNA* region of 23nt miRNA
constructs. Shown are the miRNA/miRNA* sequences
(capital letters) for miR145 23 nt construct in the miR319a
backbone (A) miR-145 23 nt construct miR/miR* structure
with mismatches at the 1 nt, 8 nt, 19 nt positions (B) miR145 23 nt sequence
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Figure 2.3: Production of three mouse miRNAs in
bioengineered plants. Gel blot analysis of RNA
samples isolated from wild type (WT) Arabidopsis and
homozygous lines expressing miR-34a, miR-143 or miR145. (A) The blot was probed for all three tumor
suppressor miRNAs. (B) A duplicate WT sample was
probed for the highly expressed endogenous plant
miRNA, miR168a. The ethidium bromide (EtBr) stained
gel is shown as loading control below the
autoradiograms.
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A

B

Natural miR319a isomiRs

Transgenic miR-143
isomiRs

9%
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natural (21 nt)

C

20 nt
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Transgenic miR-34a
isomiRs

Transgenic (21 nt)

D
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20 nt
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24 nt
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Figure 2.4: miRNA isomiR distributions in bioengineered plants.
Shown are the miRNA isomiR distribution in each independent
homozygous Arabidopsis line analyzed by next generation sequencing
(A) endogenous miR319a isomiR distribution (B) miR-34a 21 nt isomiR
distribution (C) miR-143 isomiR distribution (D) miR-145 23 nt isomiR
distribution
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CHAPTER 3
FEEDING EXPERIMENT: DIETARY DELIVERY OF MAMMALIAN
TUMOR SUPPRESSOR MIRNAS

3.1 INTRODUCTION
3.1.1 RESTORATION

OF

TUMOR SUPPRESSOR

MIRNAS

VIA INGESTION

OF

BIOENGINEERED ARABIDOPSIS
In the published Vance lab pilot experiment, ApcMin/+ mice were gavaged
with total plant RNA spiked with three validated tumor suppressor miRNAs (miR34a, miR-143, and miR-145) synthesized to have the methylation characteristic of
miRNAs produced in plants (Mlotshwa et al., 2015). The experimental approach
was to use a preventive regimen, with treatment starting before the mice
developed polyps. After five weeks of daily gavage, the tumor burden in the
miRNA-treated mice was significantly reduced compared to mice that didn’t
receive the miRNAs. Based on these results, a feeding experiment was proposed
which would replicate the design of the pilot experiment, but use miRNAs actually
produced in transgenic plants rather than synthetic ones, and also deliver the
miRNAs by incorporating the transgenic plant material into the ApcMin/+ mouse diet.

15

3.1.2 RATIONALE FOR CHOICE OF DISEASE AND MOUSE MODEL
Colorectal cancer (CRC) is the third leading cause of cancer death in both
men and women. Approximately 140,000 people in the US will be diagnosed with
the disease in 2018 and over 50,000 will die from it (Siegel et al., 2018). Even
though new screening techniques and advances in surgical treatment have
reduced the mortality rate of CRC, there is almost a 50% chance of reoccurrence
of the disease post-surgery, and greater than one third of the people who develop
the disease will die from it. Mortality rates have declined over the last decade due
to several factors, like decreased smoking, maintaining a healthy weight, reduced
red meat consumption, regular colorectal screenings and improved treatments
(Fedewa et al., 2015). Though preventative screenings can greatly reduce the risk
of ever developing CRC, many people avoid the procedure due to its invasiveness
and cost (Zauber, 2015). Another disturbing trend is the rise of CRC cases seen
in adults <50 years old, where both CRC incidences and mortality rates have been
reported to increase (Bhandari et al., 2017). These statistics illustrate the need for
new preventive strategies, and delivery of tumor suppressor miRNAs via the diet,
if successful, could have a big impact. The ApcMin/+ mouse is an in vivo model for
CRC (Corpet and Pierre, 2003), which has a heterozygous truncation of the Apc
gene. Because similar mutations in the Apc gene occur in about 80% of cases of
CRC in humans, the ApcMin/+ mouse is an excellent in vivo model for human CRC
(Haggar and Boushey, 2009). The mice develop numerous tumors in the intestine
and are commonly used to test chemopreventive therapies for CRC because the
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effect of therapies can easily be assayed by determining the effect on number of
tumors (Perkins et al., 2002).

3.1.3 THE RATIONALE FOR CHOICE TUMOR SUPPRESSOR MIR-34A, MIR-143,
AND MIR-145

The experimental approach for the earlier pilot study was to use three
different validated tumor suppressor miRNAs to optimize the chances of a
successful intervention. Based on the success of the pilot, the same combination
of tumor suppressors was chosen for the feeding experiment. Two of the three
miRNAs, miR-143 and miR-145, are co-expressed on the same primary transcript,
and often work synergistically to knock down several shared oncogenic targets
(Akao et al., 2010). They are downregulated early in CRC development (Weng et
al., 2015), and restoration of their levels inhibits growth of CRC cells in culture. In
contrast, overexpression of the two miRNAs reduces the development of tumors
in ApcMin/+ mice (Takaoka et al., 2012). The fact that these two miRNAs are
naturally co-expressed and act synergistically justifies administering the two
together for our experimental approach.
The third miRNA, miR-34a, has broad activity as a tumor suppressor in
many tumor types (Nalls et al., 2011). It has been found to regulate targets in
important cell cycle pathways, such as CDK6 in the p53 pathway and Notch 1 in
the Wnt signaling pathway (Saito et al., 2015). In contrast to miR-143 and miR145, it is down regulated a later stage of CRC progression, and may play a role in
cells acquiring the ability to spreads and invade other organs (Jin et al., 2015).
17

Restoration of miR-34 levels has been shown to induce cell apoptosis, cell cycle
arrest, and p53 transcription in vivo, making it a strong candidate for
chemopreventive approaches (Saito et al., 2015).

3.2 RESULTS AND DISCUSSION
3.2.1 DEVELOPING METHODS

FOR

DIETARY DELIVERY

OF

MAMMALIAN

TUMOR SUPPRESSOR MIRNAS PRODUCED IN BIOENGINEERED ARABIDOPSIS
THALIANA

Two major challenges had to be overcome before it was possible to do the
feeding experiment. First, a method was needed to allow miRNAs from plant
material to remain functional for long periods of time without degrading, as RNA is
relatively unstable and prone to breakdown (Garneau et al., 2007). Second, a way
was needed to incorporate the miRNAs into the mouse diet without using too great
a mass of plant tissue. Initially, using juice instead of plant tissue was tested. To
test juicing, bioengineered Arabidopsis was processed using a commercially
available juicer that separated the solid plant material from the liquid. However, a
large portion of the bioengineered miRNA was lost with the solid material, and the
remaining miRNA was unstably in juice, degrading within 24 hours at 5oC (Figure
3.2).
An alternative approach to reduce the mass of plant material for
incorporation into mouse chow, while also stabilizing the miRNA, was
lyophilization. The method chosen was lyophilization. To test this approach, fresh
Arabidopsis leaves expressing bioengineered miR-34a 21 nt were frozen in liquid
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nitrogen, ground briefly with a mortar and pestle, and lyophilized until sublimation
was complete. This method not only stabilized the miRNAs for up to 4 weeks while
stored at room temperature, it reduced the total weight of the plant material by 10fold (Figure 3.3). Thus, one gram of lyophilized plant material contained the same
amount of miRNA as ten grams of fresh tissue.
Feeding the lyophilized plant tissue to mice meant it had to be incorporated
into mouse chow, an intense procedure that involves heating. The stability of
miRNAs during incorporation into mouse chow was tested by mixing lyophilized
plant tissue with commercial standard AIN-76A mouse synthetic diet (a mixture
that is similar to purified components that would be added to the plant material to
make a balanced diet), adding water, compacting the mixture, and heating it for 8
hours at 46oC.

Lyophilization was able to stabilize the miRNAs during the

simulated chow incorporation process (Figure 3.4). Because miRNA levels were
unaffected by lyophilization, total plant mass was reduced 10-fold, and degradation
was not seen during the simulated diet incorporation process, this was the method
selected for dietary delivery of plant-produced miRNAs.

3.2.2 DESIGN OF HEALTHY MOUSE TEST DIETS
Lyophilized plant material was analyzed by a commercial company to
determine the levels of macronutrients and micronutrients in preparation for having
custom mouse diets made by a commercial supplier (Table 3.1). Based on the
results from the nutritional analysis of lyophilized Arabidopsis, two healthy mouse
diets were designed, one diet incorporating 10% Arabidopsis, and a diet that was
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matched calorically and nutritionally, but did not contain plant tissue (purified diet).
This was achieved my mixing together a set of purified ingredients (Table 3.2),
taking the input of the Arabidopsis into consideration, and ensuring the nutritional
and caloric components of the two diets were matched (Table 3.3). A bacon flavor
additive was used to increase palatability. The Arabidopsis diet contained 3.33 g
of each of the lyophilized homozygous lines bioengineered to express one of the
mammalian tumor suppressor miRNAs (miR-34a 21 nt, miR-143 and miR-145 23
nt), totaling 10 g per 100 g of chow. miRNAs are stable for two weeks room
temperature after incorporation into mouse chow, and the purified diet contained
no miRNAs (Figure 3.6).

3.2.3 DIET CONTAINING BIOENGINEERED ARABIDOPSIS

HAD

SIGNIFICANT

CHEMOPREVENTATIVE ACTIVITY IN APCMIN/+ MICE
The feeding experiment used two groups of six male ApcMin/+ mice fed either
the transgenic plant diet bioengineered to produce three tumor suppressor
miRNAs or the control nutritionally and calorically matched purified diet without
miRNAs. Mice from the two groups were weaned onto their respective diets in a
preventative regimen (starting at three weeks of age), and weights of the mice
were taken weekly, which showed that the mice in the two groups gained weight
at the same rate (Figure 3.7A). The weight of the food consumed per group was
recorded as well, showing mice on the two different diets consumed approximately
the same amount of food (Figure 3.7B). Mice were sacrificed after six weeks on
the diet (at nine weeks of age), and the number of tumors in the small and large
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intestine counted after methylene blue staining. Mice that consumed the diet
containing Arabidopsis bioengineered to express mammalian tumor suppressor
miRNAs had significantly fewer tumors (p=.0454) than mice fed the matched
purified diet (Figure 3.7). Mice fed the transgenic plant diet had an average of 21
tumors (SD 4.179), while the mice on the purified diet had an average of 32.83
tumors (SD 4.74). Thus, ingestion of plant tissues engineered to produce tumor
suppressor miRNAs had a statistically significant chemopreventive impact.

3.2.4 APCMIN/+ MICE FED THE MIR DIET HAD ELEVATED LEVELS OF MIR-34A,
MIR-143, AND MIR-145 COMPARED TO THE CONTROL GROUP

Next generation sequencing was used to determine if the reduced tumor
burden observed in the mouse group receiving the transgenic plant diet, also
showed an increase in the level of the dietary miRNAs in intestinal tissues. RNA
was isolated from a 2cm proximal section scraping of the small intestine to
measure levels of the administered miRNAs using next generation sequencing.
The two groups had their RNA samples pooled and prepared using equal amounts
of RNA from the individual members of the group: the transgenic plant diet group
(containing miRNAs) and the control purified diet group (without miRNAs). Next
generation sequencing was performed on the two pooled group samples, and the
number of reads of known miRNAs, as normalized to reads per million, was
determined. The group receiving the transgenic plant diet had higher levels of all
three administered miRNAs than those from the group receiving the control purified
diet; however, the levels of miRNAs that were not administered via the transgenic
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plant diet did not differ between the two groups (Figure 3.8A). This result raised
the possibility that the increased level of the engineered miRNAs detected in the
plant-fed mice might reflect dietary uptake of the miRNAs. However, the possibility
that uptake of plant-produced miRNA directly accounts for the observed increase
in sequence reads is unlikely because of the strong bias against detection of the
methylated plant-produced miRNAs in a background of mammalian miRNAs,
which do not have inhibiting 2’-O-methylation at the 3’ end (Raabe et al., 2014). In
addition, the increases in miR-143 and miR-145 were substantial, arguing against
attributing them to dietary uptake. Another possibility is that the dietary miRNAs
were taken up by the intestinal cells, and, although they could not be directly
detected due the methylation bias, were active in the mouse tissue.

One

consequence of their activity is that a positive feedback loop for miR-143/miR-145
would be triggered and result in up-regulation of the expression of the endogenous
gene encoding the two miRNAs (Pagliuca et al., 2013; Takaoka et al., 2012). This
scenario would explain the observed increase in the administered miRNAs as well
as the reduced levels of their known direct target mRNAs reported below.

3.2.5 APCMIN/+ MICE FED

THE MIR

DIET

HAD

DECREASED LEVELS

OF

TARGETS OF MIR-34A, MIR-143, AND MIR-145 COMPARED TO THE CONTROL
GROUP

An increase in the levels of the administered tumor suppressor miRNAs
would be predicted to result in a decrease in at least some of the direct targets of
those miRNAs. To determine if known targets were reduced, the same pooled
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RNA group samples used to measure levels of miRNAs, were analyzed by RNA
seq to determine mRNA levels. Several well-established targets of miR-34A, miR143, and miR-145 were found at reduced levels in the transgenic plant diet group
compared to those in the control synthetic diet group (Figure 3.9), including eight
known miR-143 targets (Figure 3.9A), five known miR-145 targets (Figure 3.9B),
and six known miR-34a targets (Figure 3.9C) (Davis-Dusenbery et al., 2011; Kent
et al., 2014; Zhang et al., 2009; Qian et al., 2013; Xu et al., 2017; Chen et al., 2009;
Cui et al., 2014; Manuscript and Dysfunction, 2015; Chou et al., 2016). These data
are consistent with the increased levels of the administered miRNAs observed in
the plant diet group compared to the control purified diet group, suggesting that
the detected miRNAs represent an active population. It should be noted that these
3 miRNAs have many targets, miR-34a has over 700 confirmed targets alone, the
targets examined were randomly selected based on the literature (Slabáková et
al., 2017).
Overall, these results show that mice fed a diet containing bioengineered
Arabidopsis expressing mammalian tumor suppressor miRNAs had a statistically
significant reduction in tumor burden compared to those fed a nutritionally and
calorically matched synthetic diet. In addition, when pooled RNA samples from the
two groups were analyzed by next generation sequencing, the levels of the three
administered miRNAs was increased in the plant-fed group compared to the
control group, suggesting uptake of dietary miRNAs. Furthermore, the increased
levels in the three administered miRNAs was accompanied by decreases in
numerous known direct targets of the miRNAs. These results look promising for
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the use of plants as biofactories to produce and deliver dietary miRNAs. However,
limitations in the experimental approach prevent drawing firm conclusions at this
time. First, the RNA sequencing data used pooled samples, so the statistical
significance of the results cannot be determined. Second, the chemopreventive
impact of the diet cannot definitively be attributed to the bioengineered miRNAs
produced by the plant. To unravel the role of the plant itself from the bioengineered
miRNAs would require including an additional control group receiving the same
level of non-transgenic plant tissue. Whereas the decreased tumor burden in the
plant-fed group cannot be directly attributed to the tumor suppressor miRNAs
produced by the plant, the increased levels of the bioengineered miRNAs in mouse
intestinal samples of the plant-fed group and the accompanying decrease in levels
of their direct targets, suggest that the observed chemopreventive effect may be
mediated by the dietary miRNAs. Future studies should use larger sample size,
analyze individuals rather than pooled samples, and include a control group fed
non-transgenic plant material to tease out the roles of the plant versus the
bioengineered miRNAs.
This experiment also raised the point that there may be a limit to the amount
of lyophilized plant tissue that can be incorporated into a diet before the food
becomes unpalatable. Therefore, methods aimed at increasing the concentration
of miRNAs in the sample, while simultaneously decreasing overall plant mass, are
needed. One such method may lie in a proposed delivery mechanism for plantmade miRNAs: plant exosome-like vesicles (EVs). Plant EVs, and the mechanisms
that controls loading of miRNAs into them, are discussed in the next chapter.
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A

B

C

Figure 3.1: Images of leaves, juice, and lyophilized Arabidopsis.
Three different tissue preparations for Arabidopsis thaliana. (A) Fresh
Arabidopsis leaves(B) Arabidopsis just after juicing and before a low
speed centrifuge spin (C) Arabidopsis shortly before lyophilization is
complete.

25

Juice

Leaves Pellet

Leaves

0hr 24hr 48hr 72hr WT

miR-143

Figure 3.2: miR-143 stability in juice. Gel blot analysis of
RNA samples isolated from Arabidopsis homozygous line
expressing miR-143 and WT. Time course shows stability of
miR-143 after juicing and storage at 5oC compared to fresh
WT Arabidopsis and Arabidopsis expressing miR-143. The
ethidium bromide (EtBr) stained gel is shown as loading
control below the autoradiograms.
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Figure 3.3: miR-143 and miR-34a stability in lyophilized plant
tissue. Gel blot analysis of RNA samples isolated from fresh and
lyophilized Arabidopsis bioengineered to express miR-143 and
miR-34a (A) miR-143 expression level in fresh Arabidopsis and
immediately after lyophilization. (B) Time course shows stability of
miR34a after lyophilization and storage at room temperature
compared to fresh Arabidopsis. The ethidium bromide (EtBr)
stained gel is shown as loading control below the autoradiograms.
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miR159a
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Figure 3.4: Stability of endogenous plant miR-159a during
mouse chow incorporation. Gel blot analysis of RNA samples
isolated from lyophilized Arabidopsis stored at -80oC. Lyophilized
plant tissue was subjected to mixture with a raw AIN-76A diet, adding
water, and pressure by crushing in a mortar and pestle, and tested at
46oC and room temperature condition. (Lane1) RNA isolated from
lyophilized leaves (Lane2) RNA isolated from lyophilized leaves
mixed with an AIN 76a diet mixture, water, and left at room
temperature for 8 hours (Lane3) RNA isolated from lyophilized
leaves mixed with an AIN 76a diet mixture, water, and heated at 46 oC
for 8 hours (Lane4) RNA isolated from lyophilized leaves mixed with
an AIN 76a diet mixture. The ethidium bromide (EtBr) stained gel is
shown as loading control below the autoradiograms.
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miR-145

1

2

Figure 3.5: miRNAs are stable in mouse chow incorporated in
10% Arabidopsis diet. RNA was isolated from mouse chow
containing 10% Arabidopsis after being sent out overnight on dry ice
to be incorporated into chow, then sent back overnight on dry ice and
stored at -80oC. (Lane 1) miR diet taken out of -80oC storage and a
RNA isolation was performed. (Lane 2) miR diet was stored at room
temperature for 2 weeks and another RNA isolation was performed.
The ethidium bromide (EtBr) stained gel is shown as loading control
below the autoradiograms
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Figure 3.6: Average weight of ApcMin/+ mice and average
weight of diets consumed. The weight of mice and the chow
they consumed was recorded weekly. (A) Weights of 3-week-old
mice were taken initially before being weaned onto their
perspective diets. Weights were recorded weekly, with mice
being sacrificed immediately after the week 6 weighing. (B) The
amount of diet each test group consumed was recorded weekly.
Mice were fed in a collective manner, so total weight of food
eaten was divided by the total number of mice per cage then
divided by 7 days a week.
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Figure 3.7: Average ApcMin/+ mice tumor
burden in mice consuming 10% miR or
purified diets. The small and large
intestine was removed from mice, flushed
with PBS, fixed with formaldehyde, and
stained methylene blue. A one tailed t
tested showed significantly less tumors in
the mice fed the miR diet compared to
those on the purified diet (>0.04536).
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miRNA levels in mice fed miR diet vs purified diet

miRNA fold change

miR diet
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Figure 3.8: Fold change of miRNAs in mice fed miR and
purified diets. Next generation sequencing of miRNAs and
miRNA targets was performed on pooled RNA samples from mice
fed miR and purified diets. Fold change was calculated from
reads normalized to read per million. Fold change of miR-143,
miR-145, and miR-34a in mice fed the miR and purified diets,
miR-192 and let-7b that are highly expressed control miRNAs
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Figure 3.9: Fold change of miRNA targets in mice fed miR
and purified diets. Next generation sequencing of miRNAs
and miRNA targets was performed on pooled RNA samples
from mice fed miR and purified diets. Fold change was
calculated using a normalized down and pseudo method. (A)
Fold change of miR-34a targets (B) Fold change of miR-143
targets (C) Fold change of miR-145 targets
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Table 3.1: nutritional and caloric values of lyophilized Arabidopsis
Fatty Acids Calculated as Triglycerides
Saturated Fatty Acids
0.0846 g/10g
Unsaturated Fatty Acids
0.0854 g/10g
Monounsaturated Fatty Acids
0.0154 g/10g
Polyunsaturated Fatty Acids
0.0700 g/10g
Trans Fatty Acids
0.0646 g/10g
Omega 3 Fatty Acids
0.0484 g/10g
Omega 6 Fatty Acids
0.0247 g/10g
Omega 9 Fatty Acids
0.0071 g/10g
Total Fatty Acids
0.245 g/10g
4:0 Butyric
<0.0007 g/10g
6:0 Caproic
<0.0007 g/10g
8:0 Caprylic
<0.0007 g/10g
10:0 Capric
<0.0007 g/10g
12:0 Lauric
<0.0007 g/10g
14:0 Myristic
<0.0007 g/10g
14:1 Myristoleic
<0.0007 g/10g
15:0 Pentadecanoic
<0.0007 g/10g
15:1 Pentadecenoic
<0.0007 g/10g
16:0 Palmitic
0.0782 g/10g
16:1 Palmitoleic
<0.0007 g/10g
17:0 Heptadecanoic
<0.0007 g/10g
17:1 Heptadecenoic
<0.0007 g/10g
18:0 Stearic
0.0053 g/10g
9c 18:1 Oleic
0.0071 g/10g
18:2 Linoleic
0.0247 g/10g
20:0 Arachidic
0.0009 g/10g
18:3 Gamma Linolenic
<0.0007 g/10g
20:1 Eicosenoic
<0.0007 g/10g
18:3 Linolenic
0.0484 g/10g
18:4 Octadecatetraenoic
<0.0007 g/10g
20:2 Eicosadienoic
<0.0007 g/10g
22:0 Behenic
0.0014 g/10g
22:1 Erucic
<0.0007 g/10g
20:3 Eicosatrienoic
<0.0007 g/10g
20:4 Arachidonic
<0.0007 g/10g
20:5 Eicosapentaenoic
<0.0007 g/10g
24:0 Lignoceric
0.0030 g/10g
22:5 Docosapentaenoic
<0.0007 g/10g
22:6 Docosahexaenoic
<0.0007 g/10g
Total 18:1 trans
0.0100 g/10g
Total 18:1 cis
0.0161 g/10g
Total 18:2 trans
0.0185 g/10g
Total 18:3 trans
0.0389 g/10g
Pantothenic Acid by Microbiological Method
Pantothenic Acid
0.129 mg/10g

Vitamin C (by HPLC)
Vitamin C
48.9 mg/10g
Elements by ICP ES
Aluminum
1.76 mg/10g
Barium
0.390 mg/10g
Boron
0.497 mg/10g
Calcium
328 mg/10g
Chromium
<39.7 mcg/10g
Copper
0.0916 mg/10g
Iron
2.43 mg/10g
Magnesium
99.2 mg/10g
Manganese
1.34 mg/10g
Molybdenum
<39.7 mcg/10g
Phosphorus
86.0 mg/10g
Potassium
463 mg/10g
Sodium
8.14 mg/10g
Strontium
1.07 mg/10g
Zinc
0.771 mg/10g
Amino Acids
Aspartic Acid
273 mg/10g
Threonine
121 mg/10g
Serine
123 mg/10g
Glutamic Acid
356 mg/10g
Proline
126 mg/10g
Glycine
145 mg/10g
Alanine
152 mg/10g
Valine
157 mg/10g
Isoleucine
122 mg/10g
Leucine
230 mg/10g
Tyrosine
101 mg/10g
Phenylalanine
155 mg/10g
Lysine
166 mg/10g
Histidine
54.6 mg/10g
Arginine
142 mg/10g
Cystine
19.2 mg/10g
Methionine
40.1 mg/10g
Ash
Ash
1.94 g/10g
Moisture
Moisture
0.427 g/10g
Iodine by ICP-MS
Iodine
3.51 mcg/10g
Selenium *
Selenium
0.832 mcg/10g
Carotenes
Beta Carotene 4.47 mg/10g
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Cholesterol
Cholesterol
0.093 mg/g
Carbohydrates
Total Carbohydrates
2.85 g/10g
Total Dietary Fiber
Total Dietary Fiber
2.10 g/10g
Sugar Profile
Fructose
0.02 g/10g
Glucose
0.04 g/10g
Sucrose
<0.01 g/10g
Lactose
<0.01 g/10g
Maltose
<0.01 g/10g
Galactose
<0.01 g/10g
Total Sugar
0.06 g/10g
Protein (N x 6.25) Dumas Method
Protein
4.54 g/10g
Nitrogen
0.727 g/10g
Choline
Choline
4.7 mg/10g
Calories
Calories
31.8 Cal/10g
Calories from Fat
Calories
2.21 Cal/10g
Fat by Acid Hydrolysis
Fat
0.58 g/10g
Vitamin D by LCMS
Total Vitamin D3
<0.400 IU/10g
Vitamin E (Natural)
Vitamin E
1.27 IU/10g
Vitamin K1
Vitamin K1
480 mcg/10g
Thiamin by Fluorometric Method
Thiamin
0.008 mg/10g
Riboflavin by Microbiological Method
Riboflavin
0.302 mg/10g
Niacin by Microbiological Method
Niacin
1.02 mg/10g
Pyridoxine
Pyridoxine
0.149 mg/10g
Folic Acid by Microbiological Method
Folic Acid
89.5 mcg/10g
Vitamin B12 by Microbiological Method
Vitamin B12
0.017 mcg/10g
Biotin by Microbiological Method
Biotin
1.68 mcg/10g

Table 3.2: Nutritional components added to miR and
purified diets.
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Table 3.3: Final nutritional content of miR and purified diets
Diet
Nutrient
miR Purified
Alanine
4.6
4.6
Arginine
6.4
6.4
Aspartic Acid
11.2
11.2
Beta Carotene
44.7
44.7
Biotin
0.2
0.2
Boron (Br)
5.0
5.0
C10:0 Capric
0.0
0.0
C14:0 Myristic
0.1
0.1
C16:0 Palmitic
6.4
5.9
C16:1 Palmitoleic 0.2
0.2
C18:0 Stearic
1.7
1.9
C18:1 Oleic
12.2
12.6
C18:2 Linoleic
22.3
25.3
C18:3 Linolenic
1.3
1.2
C20:0
0.0
0.0
C20:1
0.1
0.1
C22:0
0.0
0.0
C24:0
0.0
0.0
Calcium
5.2
5.2
CCarbohydrate
2.65
2.57
CFat
0.46
0.46
Chloride
1.6
1.6
Cholesterol
1.0
0.1
Choline
822
822
Chromium
2.0
2.0
Copper
6.9
6.0
CProtein
0.72
0.72
CTotal
3.83
3.75
Cystine
0.5
0.5
Disaccharides
518
510
Folic Acid
2.9
2.0
Fructose
0.2
0.0
Glucose
0.4
0.0
Glutamic Acid
35.6
35.6
Glycine
4.3
4.3
Histidine
4.8
4.8
Iodine
0.2
0.2
Iron
37.0
37.0
Isoleucine
9.6
9.6

Diet
Nutrient
miR Purified
gm/kg Leucine
14.6
14.6
gm/kg
gm/kg Lysine
13.0
13.0
gm/kg
gm/kg Magnesium
1.0
1.0
gm/kg
gm/kg Manganese
58.5
58.5
mg/kg
mg/kg Methionine
7.5
7.5
gm/kg
gm/kg Monounsaturated 12.7
13.0
gm/kg
gm/kg Niacin
40.0
40.0
mg/kg
gm/kg Pantothenic Acid 15.9
14.7
mg/kg
gm/kg Ash
3.2
3.4
gm/kg
gm/kg Carbohydrate
66.3
64.3
gm/kg
gm/kg Fat
5.1
5.1
gm/kg
gm/kg Fiber
4.8
4.8
gm/kg
gm/kg Phenylalanine
7.8
7.8
gm/kg
gm/kg Phosphorus
2.8
2.8
gm/kg
gm/kg Polysaccharides 116
133
gm/kg
gm/kg Polyunsaturated
23.3
26.0
gm/kg
gm/kg Potassium
5.4
5.5
gm/kg
gm/kg Protein
18.1
18.1
gm/kg
gm/kg Proline
18.0
18.0
gm/kg
gm/kg Pyridoxine
7.3
7.3
mg/kg
gm/kg Riboflavin
9.0
9.0
mg/kg
mg/kg Saturated
8.5
8.2
gm/kg
gm/kg Selenium
0.2
0.2
mg/kg
mg/kg Serine
10.0
10.0
gm/kg
gm/kg Sodium
1101
1019
mg/kg
mg/kg Sulfur
337
337
mg/kg
gm/kg Thiamin
6.1
6.0
mg/kg
gm/kg Threonine
7.7
7.7
gm/kg
gm/kg Tryptophan
2.0
2.0
gm/kg
gm/kg Tyrosine
10.0
10.0
gm/kg
mg/kg Valine
11.4
11.4
gm/kg
gm/kg Vitamin A
5021
5142
IU/kg
gm/kg Vitamin B12
10.0
10.0
mcg/kg
gm/kg Vitamin C
489
489
gm/kg
gm/kg Vitamin D3
1000
1000
IU/kg
gm/kg Vitamin E
121
110
IU/kg
mg/kg Vitamin K1
4.8
4.8
mg/kg
mg/kg Vitamin K3
1.0
1.0
mg/kg
gm/kg Zinc
38.1
37.0
mg/kg
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CHAPTER 4
PLANT EXOSOME-LIKE VESICLES: A POTENTIAL DELIVERY
VEHICLE FOR MIRNAS
4.1 INTRODUCTION
4.1.1 ORAL DELIVERY OF MAMMALIAN TUMOR SUPPRESSOR MIRNAS FROM
PLANTS IS AN EFFECTIVE CHEMOPREVENTATIVE STRATEGY FOR CRC
In the previous chapter, we established that incorporating lyophilized
Arabidopsis thaliana bioengineered to express mammalian tumor suppressor
miRNAs into a healthy mouse diet is an effective chemopreventive strategy for
treating CRC. The tumor burden was nearly two-fold lower in the treated mice
compared to those fed a control purified diet (n=6, p=0.045). The dosage of tumor
suppressor miRNAs provided in this feeding experiment was approximately 680
ng/day. Though the dosage is far less than the 23 ug/day of synthesized miRNA
mice received in our published pilot study, it is consistent with published results
showing miRNA in plants via a natural plant diet is delivered nearly 1000 X more
efficiently then gavaged synthetic miRNAs (Zhou et al., 2014). As exciting as these
results may be, finding alternative ways to administer plant made tumor suppressor
miRNAs should be pursued. One reason is it may be impractical to treat humans
by comprising 10% of their total daily diet with transgenic lyophilized plant tissue.
Another issue is palatability, especially with even higher concentrations of
37

lyophilized plant material. Thus, our lab sought out a method to increase the
amount of plant made mammalian tumor suppressor miRNAs delivered orally while
reducing the amount of plant material.

4.1.2 POTENTIAL UPTAKE MECHANISM OF FUNCTIONAL EXOGENOUS PLANT
MIRNAS IN MAMMALS

Since the discovery of a cross-kingdom gene regulation pathway between
plants and animals, several labs have sought out a possible mechanism that could
explain the uptake of these plant miRNAs (Witwer and Hirschi, 2014).

One

proposed mechanism is that plants package miRNAs into exosome-like vesicles
(EVs) that are taken up by the mammalian GI tract after ingestion (Zhang et al.,
2016). Plant EVs are much like animal exosomes: they are small lipid vesicles
(~100nm) that carry and protect cargo, such as proteins and miRNAs, and deliver
them throughout the organism (Record, 2013). Plant EVs have been shown to
survive the extreme conditions of the mammalian digestive tract, protecting and
delivering their contents to intestinal stem cells and macrophages (Wang et al.,
2014). Interestingly, it has been reported that plant EVs can also be delivered to
tissues via intravenous, intraperitoneal, and intranasal injections, demonstrating
they are highly versatile as a delivery vehicle (Wang et al., 2013). There is also
evidence that plant EV membranes act as natural anti-inflammatory agents, in
contrast to the toxicity associated with many synthetic delivery methods (Mu et al.,
2016).
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4.2 RESULTS AND DISCUSSION
4.2.1 EVS

FROM TRANSGENIC PLANTS CONTAIN TUMOR SUPPRESSOR

MIRNAS

To determine if EVs could be used to deliver plant-made mammalian tumor
suppressor miRNAs, we first examined whether our bioengineered miRNAs were
loaded into plant EVs. To isolate EVs from plants we followed a well-established
exosome isolation procedure (Zhuang et al., 2015).

Fresh tissue from each

bioengineered plant line was processed using a commercial juicer, a process that
separates out a large portion of plant solids, such as cell walls. The resultant plant
juice was then subjected to a series of low-speed centrifuge spins, collecting the
supernatant after each spin. The supernatant collected from the last low speed
centrifuge spin was pelleted by ultracentrifugation. RNA was isolated from the
pellet, which contained the plant EV fraction, and analyzed by RNA gel blot to
determine the level of each bioengineered miRNA. Both miR-143 and miR-34a
were found at levels comparable to that of an endogenous plant miRNA, miR159a
(Figure 4.1). These data demonstrate that plant produced mammalian tumor
suppressor miRNAs can be packaged into EVs, thereby providing a potential
delivery method for plant-made miRNAs that are packaged in those EVs.
However, miR-145 was found at much lower levels in the EV fraction, pointing to
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the importance of defining the criteria that control the packaging of miRNAs into
these vesicles.

4.2.2 FURTHER PURIFICATION OF CRUDE EV PREP
Though the crude EV preparations contain a high amount of miR-143 and
miR-34a, it was desirable to purify the EVs if it could be done without the need for
time-consuming and/or expensive additional steps.

The pellet formed after

ultracentrifugation consists of two visibly different layers: a top layer of a clear waxy
substance, and a bottom dark green layer that contained a large amount of plant
debris. It was discovered that the two layers could easily separate with gentle
pipetting using phosphate buffered saline (PBS), causing the top layer to literally
float to the top of the PBS. This floating layer was analyzed by transmission
electron microscope (TEM) to verify that the preparation contained EV-like vesicles
(Figure 4.2). RNA was isolated from both layers and RNA gel blot analysis was
used to show that the upper floating layer contained a higher concentration of miR143 and miR-34a than the green bottom layer (Figure 4.3). The bottom layer also
contained a higher amount of total RNA on average (~200μg) than the top
layer(~60μg). This quick and cost-effective method of EV enrichment will be useful
in future studies where large quantities of EVs are needed in feeding experiments.

4.2.3 LYOPHILIZATION OF EVS STABILIZED MIRNAS
Lyophilization of whole plant tissues was used to stabilize and deliver plantmade mammalian tumor suppressor miRNAs in the previous feeding experiment,
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but it was unknown if the miRNAs in the plant EV fraction would be stabilized by
lyophilization.

However, lyophilization has often been used to stabilize

nanovesicles preparations for long periods of time (Greening et al., 2015). To test
the stability of miRNAs packaged into plant EVs, the EV fraction was isolated from
Arabidopsis thaliana bioengineered to express miR-143. RNA was isolated from
a portion of the EV fraction immediately after isolated, and the remaining portion
of the EV fraction was lyophilized overnight.

After lyophilization, the EV

preparation was incubated at room temperature, and RNA isolation performed
every two days over the course of six days. We found that miRNAs were stable
for at least six days in EVs stored at room temperature after lyophilization (Figure
4.4), raising the possibility that the EV fraction of the lyophilized plant material from
the feeding experiment may have been the acting delivery mechanism in the
feeding experiment.

4.2.4 ALTERNATIVE CONSTRUCT DESIGNS

OF MIR-145 TO

IMPROVE

PACKAGING EFFICIENCY INTO EVS
Our results show that bioengineered miR-143 and miR-34a are packaged
into plant exosomes in transgenic plants, but that miR-145 is present in the EV
fraction at much lower levels. The majority of plant miRNAs are 21 nt long and start
with a 5’U, a characteristic found in both miR-34a and miR-143 (Lee et al., 2015;
Laubinger et al., 2008; Bologna et al., 2013). In contrast, miR-145 has neither of
these highly conserved traits, as it is 23 nt in length and starts with a 5’G (Figure
4.5A). In plants, small RNAs that are 24 nt long are associated with transcriptional
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silencing and are expected to stay in the nucleus (Melnyk et al., 2011). The 5’
nucleotide of miRNAs also plays a role in a small RNA’s destiny as either a
transcriptional or translational silencing small RNA (Chen, 2016).

Therefore,

several constructs were designed to determine if the either the 5’ nucleotide or the
size of the miRNA plays a role in loading into plant EVs.
To determine if the loading of miR-145 into EVs is determined by the 5’
nucleotide, a construct was designed replacing the 5’G with a 5’U (Figure 4.5B).
To determine if the loading of miR-145 into EVs is determined by length, a 21nt
miR-145 construct was designed by removing two nucleotides from the 3’ end
(Figure 4.5C). An additional construct was made that was designed to change
both of these features: the 5’ nucleotide was changed from G to U and two
nucleotides were removed from the 3’ end. This construct would be used to
determine if a combination of these two factors was needed to influence loading
into EVs (Figure 4.5D). Cloning of miRNA constructs and generation of transgenic
Arabidopsis thaliana lines was carried out as previously described in section 2.2.2.
Changing the 5’ nucleotide and/or removing two nucleotides from the 3’ end of
miR-145 should have no impact on miRNA functionality, as the seed region (a
highly conserved region on miRNAs needed for target recognition in mammals), is
located at nucleotides 2-7 from the 5’ end of miRNA sequence (Mullany et al.,
2016).
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4.2.5 THE 5’ POSITION DETERMINES LOADING OF MIR-145 INTO EVS.
To determine if the modified versions of miR-145 were packaged into the
plant EV fraction, EV preparations were prepared for each of transgenic lines
expressing those constructs as previously described in section 4.2.2. Using RNA
gel blot analysis, the expression levels of each miR-145 version in the EV fraction
was determined as compared to the overall level of expression in fresh leaves of
the plant (Figure 4.6). The transgenic plant lines all expressed high levels of the
miR-145 version they were engineered to produce in the whole plant tissues.
However, loading into the plant exosome fraction was greatly enhanced in each of
the modified miR-145 versions with a 5’U instead of the natural 5’G. In contrast,
loading of the miR-145 versions was unaffected by size. Overall, these results
point to a key role of the 5’ nucleotide in exosome loading, and are an important
first step in defining the characteristics that regulate loading of miRNAs into plant
exosomes.

43

miR-34a

miR-143

miR-145

miR159a

Figure 4.1: Levels of miRNAs loaded into EVs.
EVs were isolated from a mixture of equal amounts
of our three transgenic plant lines. 10 µg of RNA
isolated from the exosomes was loaded into each
of four lanes of a small RNA gel. The resulting blot
was cut to separate the four lanes, and each was
hybridized separately for miR-34a, mir-143, miR145, or the endogenous plant miR159a. The
ethidium bromide (EtBr) stained gel is shown as
loading control below the autoradiograms.
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Figure 4.2: Image of EVs. A transmission electron microscope (TEM)
was used to capture an image of plant EVs after exosome preparation.
After EVs were pelleted by ultracentrifugation and resuspended in
PBS they were imaged using a TEM. Black arrows indicate EV
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Whole
pellet

Top
layer

Bottom
layer

miR-143

Figure 4.3: miR-143 localization in floating and nonfloating EV prep. EVs were isolated from a transgenic
plant lines expressing miR-143. PBS was used to
separate the floating layer from the non-floating layer,
these layers were compared to a whole unseparated EV
pellet. 10 µg of RNA isolated from each EV fraction were
loaded into a small RNA gel. The ethidium bromide
(EtBr) stained gel is shown as loading control below the
autoradiograms.
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Days 0

2

4

6

miR-143

Figure 4.4: Stability of miR-143 in EVs after
lyophilization.
EVs were isolated from a
transgenic plant lines expressing miR-143 and
resuspended in PBS, with RNA isolated
immediately after EV prep. The EV prep was then
lyophilized and left at room temperature for 6 days,
with RNA being isolated at 2, 4, and 6 days. 10 µg
of RNA isolated from each EV lyophilization and
were loaded into a small RNA gel. The ethidium
bromide (EtBr) stained gel is shown as loading
control below the autoradiograms.
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Figure 4.5: Alternative size and starting nucleotide
constructs of miR-145. Constructs changing the size of miR145 and the 5’ nucleotide were designed to determine if they
were factors in EV loading. Nucleotides highlighted in yellow
have been replace with a U. Areas highlighted in red are where
nucleotides were removed to generate a 21 nt construct (A)
miR-145 23 nt 5’G (B) miR-145 23 nt 5’U (C) miR-145 5’G 21
nt (D) miR-145 21 nt 5’U
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A
miR-145
23 nt

B

Leaves
5’G 5’U

Leaves
5’G
5’U

EVs
5’G

5’U

EVs
5’G

5’U

miR-145
21 nt

Figure 4.6: levels of miR-145 constructs loaded into
EVs. EVs were isolated from four transgenic lines plant
lines. 10 µg of RNA was isolated from fresh Arabidopsis
tissue and EV preps, then loaded into each of 8 lanes of
a small RNA gel. (A) Levels of miR-145 23 nt with a 5’G
and a 5’U are compared in both fresh Arabidopsis and
EVs. (B) Levels of miR-145 21 nt with a 5’G and a 5’U
are compared in both fresh Arabidopsis and EVs. The
ethidium bromide (EtBr) stained gel is shown as loading
control below the autoradiograms.
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CHAPTER 5
MATERIALS AND METHODS
Tumor suppressor miRNA constructs
The tumor suppressor miRNAs inserts were generated using the following
gene blocks purchased from Integrated DNA Technologies.

miR-34a 21 nt
cacccaaacacacgctcggacgcatattacacatgttcatacacttaatactcgctgttttgaattgatgttttagga
atatatatgtagCACCCAGCTAAGAGACTGCCTtcacaggtcgtgatatgattcaattagcttccgac
tcattcatccaaataccgagtcgccaaaattcaaactagactcgttaaatgaatgaatgatgcggtagacaaatt
ggatcattgattctctttgaTGGCAGTGTCTTAGCTGGTTGctctcttttgtattccaattttcttgattaat
ctttcctgcacaaaaacatgcttgatccactaagtgacatatatgctgccttcgtatatatagttctggtaaaattaac
attttgggtttatctttatttaaggcatcgccatg

miR-143
cacccaaacacacgctcggacgcatattacacatgttcatacacttaatactcgctgttttgaattgatgttttagga
atatatatgtagaGAACTACAGTGCTACATCTCTtcacaggtcgtgatatgattcaattagcttccga
ctcattcatccaaataccgagtcgccaaaattcaaactagactcgttaaatgaatgaatgatgcggtagacaaat
tggatcattgattctctttgaTGAGATGAAGCACTGTAGCTCtctctcttttgtattccaattttcttgattaa
tctttcctgcacaaaaacatgcttgatccactaagtgacatatatgctgccttcgtatatatagttctggtaaaattaa
cattttgggtttatctttatttaaggcatcgccatg
50

miR-145 23 nt 5’G
cacccaaacacacgctcggacgcatattacacatgttcatacacttaatactcgctgttttgaattgatgttttagga
atatatatgtagaAGGGTCCTGGGAATACTGGAGtcacaggtcgtgatatgattcaattagcttccg
actcattcatccaaataccgagtcgccaaaattcaaactagactcgttaaatgaatgaatgatgcggtagacaa
attggatcattgattctctttgaGTCCAGTTTTCCCAGGAATCCCTtctctcttttgtattccaattttcttg
attaatctttcctgcacaaaaacatgcttgatccactaagtgacatatatgctgccttcgtatatatagttctggtaaa
attaacattttgggtttatctttatttaaggcatcgccatg

miR-145 23 nt 5’U
cacccaaacacacgctcggacgcatattacacatgttcatacacttaatactcgctgttttgaattgatgttttagga
atatatatgtagaAGGGTCCTGGGAATACTGGAUtcacaggtcgtgatatgattcaattagcttccg
actcattcatccaaataccgagtcgccaaaattcaaactagactcgttaaatgaatgaatgatgcggtagacaa
attggatcattgattctctttgaUTCCAGTTTTCCCAGGAATCCCTtctctcttttgtattccaattttcttg
attaatctttcctgcacaaaaacatgcttgatccactaagtgacatatatgctgccttcgtatatatagttctggtaaa
attaacattttgggtttatctttatttaaggcatcgccatg

miR-145 21 nt 5’G
cacccaaacacacgctcggacgcatattacacatgttcatacacttaatactcgctgttttgaattgatgttttagga
atatatatgtagGGCTTCCTGGGAATACTGGAGtcacaggtcgtgatatattcaattagcttccgact
cattcatccaaataccgagtcgccaaaattcaaactagactcgttaaatgaatgaatgatgcggtagacaaattg
gatcattgattctctttgaGTCCAGTTTTCCCAGGAATCCctctcttttgtattccaattttcttgattaatctt
tcctgcacaaaaacatgcttgatccactaagtgacatatatgctgccttcgtatatatagttctggtaaaattaacatt
ttgggtttatctttatttaaggcatcgccatg
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miR-145 21 nt 5’U
cacccaaacacacgctcggacgcatattacacatgttcatacacttaatactcgctgttttgaattgatgttttagga
atatatatgtagGGCTTCCTGGGAATACTGGATtcacaggtcgtgatatattcaattagcttccgact
cattcatccaaataccgagtcgccaaaattcaaactagactcgttaaatgaatgaatgatgcggtagacaaattg
gatcattgattctctttgaTTCCAGTTTTCCCAGGAATCCctctcttttgtattccaattttcttgattaatctt
tcctgcacaaaaacatgcttgatccactaagtgacatatatgctgccttcgtatatatagttctggtaaaattaacatt
ttgggtttatctttatttaaggcatcgccatg

Gene block product was inserted into the pENTR vector using the Invitrogen
pENTR Directional Cloning Kit (K2400). These entry vectors were recombined
with pSITE-0A destination vector using Gateway LR Clonase Enzyme Mix
(Invitrogen, 11791).

Generation of transgenic Arabidopsis thaliana lines
All Arabidopsis plants used to establish transgenic lines were grown at 23˚C
in long day conditions.

All Arabidopsis plants were of the Columbia (Col-0)

ecotype. Agrobacterium tumefaciens strain GV3101 was transformed with pSITE
destination vector containing tumor suppressor miRNA constructs and grown
overnight at 28oC in 30 mL of LB medium with antibiotics rifampicin, carbenicillin,
and kanamycin at concentrations of 50, 100, and 50 g/mL, respectively. The
overnight culture was added to 300 mL of fresh medium with the same antibiotics
and grown to the stationary phase (OD600 -2.0). Cells were harvested by
centrifuging at 5500g for 20 min. The pellet was resuspended in infiltration medium
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(5% sucrose, 0.05% Silwett L-77) to obtain the desired density (OD600 of 0.8 or
>2.0). Plants were inoculated

by submersing inflorescences in the bacteria

suspension (Clough and Bent, 1998). Saran wrap was then used to provide a high
humidity environment and plants were placed in darkness for 10 h. Seeds were
collected when all siliques were dry then disinfected with 95% ethanol for 10 min
and 0.1% Tween 20 detergent for 15 min and rinsed twice with 100% ethanol.
Once dried they were placed in LB with kanamycin (50 g/mL), with 300-400 seeds
per Petri dish. Seeds were incubated for approximately 10 d, until plants reached
the 4-leaf stage, to ensure kanamycin resistance. Transformants were
transplanted into heavily moistened potting soil where plants and grown under long
day conditions until seeds set. Seeds were collected, disinfected, and placed on
selective LB KAN media again. Transformants from lines expressing resistance
at a ¾ ratio were transplanted into heavily moistened potting soil where plants and
grown under long day conditions until seeds set.

Seeds were collected,

disinfected, and placed on selective LB Kan media again. Lines expressing 100%
Kan resistance where RNA isolation was performed from whole population, using
TRIzol reagent (Life Technologies) as specified in the protocol,

to check

expression level by RNA gel blot analysis previously described(Mlotshwa et al.,
2005).

total plant RNA
Total plant RNA was isolated from flash frozen Arabidopsis thaliana, using
TRIzol reagent (Life Technologies) according to the manufacturer’s instructions.

53

Total plant RNA contains all high and low molecular weight RNA species present
in the plant. Therefore, it contains all endogenous plant RNAs, including, for
example, mRNAs, tRNAs and rRNA, as well as the entire set of endogenous plant
miRNAs. In general, there is no homology between plant and animal miRNAs,
although one bioinformatics study indicated that plants and animals share
members of the miR854 family (Millar and Waterhouse, 2005; Arteaga-Vazquez et
al., 2006; Jones-Rhoades et al., 2006)

RNA isolation from mouse tissue
Flash frozen intestinal sections for RNA isolation were stored at -70oC. The
frozen tissues were disrupted with a hand-held polytron at maximum speed in the
presence of 10 ml of TRIzol reagent (Life Technologies) per gram of tissue, and
total RNA was isolated according to manufacturer instructions.

RNA gel blots
RNAs (10μg) were resolved on denaturing polyacrylamide gels (20% PAA,
19:1 acrylamide/bis, 7 M urea) in 0.5 × TBE as described (Mlotshwa et al., 2005).
The membranes were probed with specific oligodeoxynucleotides (ODNs)
complementary

to

the

annotated

mouse

miRNAs

miR-34a

ACAACCAGCTAAGACACTGCCA, miR-143 GAGCTACAGTGCTTCATCTCA,
miR-145

AGGGATTCCTGGGAAAACTGGAC,

miR159a

UUUGGAUUGAAGGGAGCUCUA, miR168a UCGCUUGGUGCAGGUCGGGAA
(miRBase). The ODNs were labeled with [γ32P] ATP (5000 Ci/mmol, Hartmann
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Analytics) Specific miRNA probes were prepared by end-labeling antisense
oligonucleotides with T4 polynucleotide kinase (New England Biolabs). Prehybridizations and hybridizations were carried out under the same conditions at
42°C using Ambion ULTRAhyb oligo hybridization solution. After hybridization, the
membranes were washed three times in a low-stringency buffer solution (2 × SSC
and 0.1% SDS) for 20 minutes.

miRNA next generation sequencing
Libraries were generated using NEBNext Ultra II RNA Library Prep Kit for
Illumina (New England Biolabs), and libraries were generated according to
manufacturer instructions. Libraries were sent over night on ice to University of
Alabama Birmingham, The Heflin Center Genomics Core. Quality control was
performed on a HighSensitivity DNA chip on the BioAnalzyer followed by 75bp
sequence reads single end read performed on the NextSeq500. Sequencing
generated between 15 million and 25 million reads. Sequencing analysis was
performed on CLC Genomics Workbench (Qiagen), libraries were analyzed
according to manufacturer instructions. High quality reads were annotated to
miRbase then normalized to reads per million.

mRNA next generation sequencing
Libraries and sequencing was performed on pooled miR and purified diet samples
were generated University of Alabama Birmingham, The Heflin Center Genomics
Core. They generated the library by subjecting samples to two rounds of polyA
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selection followed using the Agilent SureSelect Direction RNA-Seq kit using the
manufacturer’s protocol. Quality control was performed on a HighSensitivity DNA
chip on the BioAnalzyer followed by 75bp sequence reads single end read
performed on the NextSeq500. Sequencing generated between 15 million and 25
million reads. Sequencing analysis was performed on CLC Genomics Workbench
(Qiagen), libraries were analyzed according to manufacturer instructions. High
quality reads were annotated then normalized down to the sample with the lowest
number of reads.

mouse Strains

C57BL/6J-ApcMin/J mice (ApcMin/+) were purchased from Jackson
Laboratories (Bar Harbor, ME, USA) but were bred and maintained at the Mouse
Core Facility of the Center for Colon Cancer Research at the University of South
Carolina (USC), Columbia, SC. All aspects of the animal experiments were
conducted in accordance with the guidelines and approval of the USC Institutional
Animal Care and Use Committee. The ApcMin/+ mouse model of colon cancer is a
genetic model of the disease. These mice are relatively healthy and long lived, in
contrast to orthotopic models of colon cancer, which quickly succumb to the
disease. ApcMin/+ mice do not start to get sick until about 18 weeks of age, at which
point they become anemic. They develop muscle wasting at about 20 weeks of
age and typically die when about six months old. Our treatment regimen (see
below) ended long before ApcMin/+ mice show any signs of illness.
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Experimental diet protocol
Four-week-old male ApcMin/+ mice were divided into 2 treatment groups of
six mice each. The treatment groups corresponded to a diet with either 1) 10%
Arabidopsis thaliana lines bioengineered to express miR-34a, miR-143, and miR145 2) purified diet matched nutritionally and calorically. Treatment diets above
began when the mice were four weeks old and continued daily for six weeks. This
time frame is a standard preventive regimen for experiments using ApcMin/+ mice.
No weight loss was observed in any of the mice during the entire 42 days of
treatment. Because one of the best signs of toxicity of therapeutic treatments has
been loss of weight within 3-5 days of treatment, the absence of weight loss in our
animals indicates that our treatments had no obvious toxicity. In addition, the
animals did not develop anemia during the experiment, as indicated by normal (as
opposed to pale) coloration of extremities, further arguing against toxic side
effects. Mice were humanely sacrificed by cervical dislocation after administration
of anesthesia using isoflurane by inhalation. The small and large intestines were
removed, flushed with phosphate buffered saline, and sliced longitudinally. The
small intestine was divided into four equal segments with the colon treated as the
fifth segment. Sections for RNA isolation were flash frozen on dry ice, and
segments for determination of tumor burden were fixed in 10% formalin and
stained with 0.002% methylene blue. Tumors were counted under a dissecting
microscope by a single highly experienced investigator, who was blinded to the
treatments.
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Plant exosome isolation
Plant juice was collected using the omega brand vert low speed juicing
system. Juice collected was subjected to several low speed spins at 5oC. Spins
were as follows, 10 minutes at 1,000g, the supernatant was collected and spun for
20 minutes at 3,000g, and finally the supernatant was collected and spun for 40
minutes at 10,000g. The supernatant collected from low speed spins is subjected
to an ultracentrifuge spin at 15oC, at 150,000g for 90 minutes. Supernatant is
discarded, and the pellet is resuspended with PBS. To separate the top layer of
the pellet from the bottom layer PBS was lightly pipetted over the top of the pellet.
Exosomes collected and resuspend in PBS is stored at -80oC (Wang et al., 2013).

58

REFERENCES
Akao, Y., Y. Nakagawa, I. Hirata, A. Iio, T. Itoh, K. Kojima, R. Nakashima, Y.
Kitade, and T. Naoe. 2010. Role of anti-oncomirs miR-143 and-145 in human
colorectal tumors. Cancer Gene Ther. 17:398–408. doi:10.1038/cgt.2009.88.
Arteaga-Vazquez, M., J. Caballero-Perez, and J.-P. Vielle-Calzada. 2006. A
Family of MicroRNAs Present in Plants and Animals. Plant Cell Online.
18:3355–3369. doi:10.1105/tpc.106.044420.
Bhandari, A., M. Woodhouse, and S. Gupta. 2017. Colorectal cancer is a leading
cause of cancer incidence and mortality among adults younger than 50 years
in the USA: A SEER-based analysis with comparison to other young-onset
cancers. J. Investig. Med. 65:311–315. doi:10.1136/jim-2016-000229.
Bologna, N.G., A.L. Schapire, and J.F. Palatnik. 2013. Processing of plant
microRNA

precursors.

Brief.

Funct.

Genomics.

12:37–45.

doi:10.1093/bfgp/els050.
Chen,

X.

2016.

HHS

Public

Access.

21–44.

doi:10.1146/annurev.cellbio.042308.113417.Small.
Chen, X., X. Guo, H. Zhang, Y. Xiang, J. Chen, Y. Yin, X. Cai, K. Wang, G. Wang,
Y. Ba, L. Zhu, J. Wang, R. Yang, Y. Zhang, Z. Ren, K. Zen, J. Zhang, and
C.Y. Zhang. 2009. Role of miR-143 targeting KRAS in colorectal
tumorigenesis. Oncogene. 28:1385–1392. doi:10.1038/onc.2008.474.

59

Chin, A.R., M.Y. Fong, G. Somlo, J. Wu, P. Swiderski, X. Wu, and S.E. Wang.
2016. Cross-kingdom inhibition of breast cancer growth by plant miR159. Cell
Res. 26:1–12. doi:10.1038/cr.2016.13.
Chou, C.H., N.W. Chang, S. Shrestha, S. Da Hsu, Y.L. Lin, W.H. Lee, C.D. Yang,
H.C. Hong, T.Y. Wei, S.J. Tu, T.R. Tsai, S.Y. Ho, T.Y. Jian, H.Y. Wu, P.R.
Chen, N.C. Lin, H.T. Huang, T.L. Yang, C.Y. Pai, C.S. Tai, W.L. Chen, C.Y.
Huang, C.C. Liu, S.L. Weng, K.W. Liao, W.L. Hsu, and H. Da Huang. 2016.
miRTarBase 2016: Updates to the experimentally validated miRNA-target
interactions

database.

Nucleic

Acids

Res.

44:D239–D247.

doi:10.1093/nar/gkv1258.
Clapé, C., V. Fritz, C. Henriquet, F. Apparailly, P.L. Fernandez, F. Iborra, C.
Avancès, M. Villalba, S. Culline, and L. Fajas. 2009. miR-143 interferes with
ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS
One. 4:1–8. doi:10.1371/journal.pone.0007542.
Clough, S.J., and A.F. Bent. 1998. Floral dip: A simplified method for
Agrobacterium-mediated transformation of Arabidopsis thaliana. Plant J.
16:735–743. doi:10.1046/j.1365-313X.1998.00343.x.
Corpet, D.E., and F. Pierre. 2003. Point : From Animal Models to Prevention of
Colon Cancer . Systematic Review of Chemoprevention in Min Mice and
Choice of the Model System Point : From Animal Models to Prevention of
Colon Cancer . Systematic Review of Chemoprevention in Min Mice and Choi.
Cancer Epidemiol. Biomarkers Prev. 12:391–400.
Cui, S.Y., R. Wang, and L.B. Chen. 2014. MicroRNA-145: A potent tumour

60

suppressor that regulates multiple cellular pathways. J. Cell. Mol. Med.
18:1913–1926. doi:10.1111/jcmm.12358.
Davis-Dusenbery, B.N., M.C. Chan, K.E. Reno, A.S. Weisman, M.D. Layne, G.
Lagna, and A. Hata. 2011. Down-regulation of Krüppel-like Factor-4 (KLF4)
by microRNA-143/145 is critical for modulation of vascular smooth muscle cell
phenotype by transforming growth factor-β and bone morphogenetic protein
4. J. Biol. Chem. 286:28097–28110. doi:10.1074/jbc.M111.236950.
Fedewa, S.A., A.G. Sauer, R.L. Siegel, and A. Jemal. 2015. Prevalence of Major
Risk Factors and Use of Screening Tests for Cancer in the United States.
Cancer

Epidemiol.

Biomarkers

Prev.

24:637–652.

doi:10.1158/1055-

9965.EPI-15-0134.
Gambari, R., E. Brognara, D.A. Spandidos, and E. Fabbri. 2016. Targeting
oncomiRNAs and mimicking tumor suppressor miRNAs: Ew trends in the
development of miRNA therapeutic strategies in oncology (Review). Int. J.
Oncol. 49:5–32. doi:10.3892/ijo.2016.3503.
Garneau, N.L., J. Wilusz, and C.J. Wilusz. 2007. The highways and byways of
mRNA decay. Nat. Rev. Mol. Cell Biol. 8:113–126. doi:10.1038/nrm2104.
Greening, D.W., D.W. Greening, R. Xu, H. Ji, B.J. Tauro, and R.J. Simpson. 2015.
Proteomic Profiling. 1295.
Grimson, A., K.K.H. Farh, W.K. Johnston, P. Garrett-Engele, L.P. Lim, and D.P.
Bartel. 2007. MicroRNA Targeting Specificity in Mammals: Determinants
beyond

Seed

Pairing.

Mol.

doi:10.1016/j.molcel.2007.06.017.

61

Cell.

27:91–105.

Haggar, F. a, and R. Boushey. 2009. Colorectal Cancer Epidemiology : Incidence
, Mortality , Survival , and Risk Factors. Clin. Colon Rectal Surg. 6:191–197.
doi:10.1055/s-0029-1242458.
Hirschi, K.D., G.J. Pruss, and V. Vance. 2015. Dietary delivery: A new avenue for
microRNA

therapeutics?

Trends

Biotechnol.

33:431–432.

doi:10.1016/j.tibtech.2015.06.003.
Jin, D.J., Y.T. Fang, Z.G. Li, Z. Chen, and J. Bin Xiang. 2015. Epithelialmesenchymal transition-associated microRNAs in colorectal cancer and drugtargeted

therapies

(Review).

Oncol.

Rep.

33:515–525.

doi:10.3892/or.2014.3638.
Jones-Rhoades, M.W., D.P. Bartel, and B. Bartel. 2006. MicroRNAS and their
regulatory

roles

in

plants.

Annu.

Rev.

Plant

Biol.

57:19–53.

doi:10.1146/annurev.arplant.57.032905.105218.
Kano, M., N. Seki, N. Kikkawa, L. Fujimura, I. Hoshino, Y. Akutsu, T. Chiyomaru,
H. Enokida, M. Nakagawa, and H. Matsubara. 2010. MiR-145, miR-133a and
miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal
squamous

cell

carcinoma.

Int.

J.

Cancer.

127:2804–2814.

doi:10.1002/ijc.25284.
Kent, O.A., M.N. McCall, T.C. Cornish, and M.K. Halushka. 2014. Lessons from
miR-143/145: The importance of cell-type localization of miRNAs. Nucleic
Acids Res. 42:7528–7538. doi:10.1093/nar/gku461.
Laubinger, S., T. Sachsenberg, G. Zeller, W. Busch, J.U. Lohmann, G. Rätsch,
and D. Weigel. 2008. Dual roles of the nuclear cap-binding complex and

62

SERRATE in pre-mRNA splicing and microRNA processing in Arabidopsis
thaliana.

Proc.

Natl.

Acad.

Sci.

U.

S.

A.

105:8795–800.

doi:10.1073/pnas.0802493105.
Lee, W.C., S.H. Lu, M.H. Lu, C.J. Yang, S.H. Wu, and H.M. Chen. 2015.
Asymmetric bulges and mismatches determine 20-nt microRNA formation in
plants. RNA Biol. 12:1054–1066. doi:10.1080/15476286.2015.1079682.
Lewis, B.P., C.B. Burge, and D.P. Bartel. 2005. Conserved seed pairing, often
flanked by adenosines, indicates that thousands of human genes are
microRNA targets. Cell. 120:15–20. doi:10.1016/j.cell.2004.12.035.
Liang, G., H. He, Y. Li, and D. Yu. 2012. A new strategy for construction of artificial
miRNA vectors in Arabidopsis. Planta. 235:1421–1429. doi:10.1007/s00425012-1610-5.
Manuscript, A., and E. Dysfunction. 2015. NIH Public Access. 25:713–724.
doi:10.1097/MCA.0000000000000178.Endothelial.
Martinez-Trujillo, M., V. Limones-Briones, J.L. Cabrera-Ponce, and L. HerreraEstrella. 2004. Improving transformation efficiency ofArabidopsis thaliana by
modifying the floral dip method. Plant Mol. Biol. Report. 22:63–70.
doi:10.1007/BF02773350.
Melnyk, C.W., A. Molnar, A. Bassett, and D.C. Baulcombe. 2011. Mobile 24 nt
small RNAs direct transcriptional gene silencing in the root meristems of
Arabidopsis

thaliana.

Curr.

Biol.

21:1678–1683.

doi:10.1016/j.cub.2011.08.065.
Millar, A.A., and P.M. Waterhouse. 2005. Plant and animal microRNAs: Similarities

63

and differences. Funct. Integr. Genomics. 5:129–135. doi:10.1007/s10142005-0145-2.
Mlotshwa, S., G.J. Pruss, J.L. MacArthur, M.W. Endres, C. Davis, L.J. Hofseth,
M.M. Peña, and V. Vance. 2015. A novel chemopreventive strategy based on
therapeutic

microRNAs

produced

in

plants.

Cell

Res.

25:521–4.

doi:10.1038/cr.2015.25.
Mlotshwa, S., S.E. Schauer, T.H. Smith, A.C. Mallory, J.M. Herr, B. Roth, D.S.
Merchant, A. Ray, L.H. Bowman, and V.B. Vance. 2005. Ectopic DICERLIKE1 expression in P1/HC-Pro Arabidopsis rescues phenotypic anomalies
but not defects in microRNA and silencing pathways. Plant Cell. 17:2873–85.
doi:10.1105/tpc.105.036608.
Mu, J., X. Zhuang, Q. Wang, H. Jiang, Z. Deng, L. Zhang, S. Kakar, Y. Jun, D.
Miller, and H. Zhang. 2016. Interspecies communication between plant and
mouse gut host cells through edible plant derived exosome-like nanoparticles.
58:1561–1573. doi:10.1002/mnfr.201300729.Interspecies.
Mullany, L.E., J.S. Herrick, R.K. Wolff, and M.L. Slattery. 2016. MicroRNA Seed
Region Length Impact on Target Messenger RNA Expression and Survival in
Colorectal

Cancer.

PLoS

One.

11:e0154177.

doi:10.1371/journal.pone.0154177.
Nalls, D., S.N. Tang, M. Rodova, R.K. Srivastava, and S. Shankar. 2011. Targeting
epigenetic regulation of mir-34a for treatment of pancreatic cancer by
inhibition

of

pancreatic

cancer

doi:10.1371/journal.pone.0024099.

64

stem

cells.

PLoS

One.

6.

Pagliuca, a, C. Valvo, E. Fabrizi, S. di Martino, M. Biffoni, D. Runci, S. Forte, R.
De Maria, and L. Ricci-Vitiani. 2013. Analysis of the combined action of miR143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a
coordinate

program

of

gene

repression.

Oncogene.

32:4806–13.

doi:10.1038/onc.2012.495.
Pastrello, C., M. Tsay, M. Abovsky, E. Pasini, E. Shirdel, M. Angeli, T. Tokar, J.
Jamnik, M. Kotlyar, A. Juriscova, J. Kostopoulos, A. El-Sohemy, and I.
Jurisica. 2016. Circulating plant miRNAs can regulate human gene expression
in vitro. Sci. reports (In Press. 1–9. doi:10.1038/srep32773.
Perkins, S., R.D. Verschoyle, K. Hill, S. Perkins, R.D. Verschoyle, K. Hill, I.
Parveen, M.D. Threadgill, R.A. Sharma, M.L. Williams, W.P. Steward, and
A.J. Gescher. 2002. Chemopreventive Efficacy and Pharmacokinetics of
Curcumin in the Min / + Mouse , a Model of Familial Adenomatous Polyposis
Chemopreventive Efficacy and Pharmacokinetics of Curcumin in the Min / ϩ
Mouse , a Model of Familial Adenomatous Polyposis 1. 11:535–540.
Pirŕ, S., L. Zanella, M. Kenzo, C. Montesano, A. Minutolo, M. Potesta, M.S. Sobze,
A. Canini, M. Cirilli, R. Muleo, V. Colizzi, and A. Galgani. 2016. MicroRNA from
moringa oleifera: Identification by high throughput sequencing and their
potential contribution to plant medicinal value. PLoS One. 11:1–25.
doi:10.1371/journal.pone.0149495.
Pramanik, D., N.R. Campbell, C. Karikari, R. Chivukula, O. a Kent, J.T. Mendell,
and A. Maitra. 2011. Restitution of tumor suppressor microRNAs using a
systemic nanovector inhibits pancreatic cancer growth in mice. Mol. Cancer

65

Ther. 10:1470–80. doi:10.1158/1535-7163.MCT-11-0152.
Qian, X., J. Yu, Y. Yin, J. He, L. Wang, Q. Li, L.Q. Zhang, C.Y. Li, Z.M. Shi, Q. Xu,
W. Li, L.H. Lai, L.Z. Liu, and B.H. Jiang. 2013. MicroRNA-143 inhibits tumor
growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in
colorectal cancers. Cell Cycle. 12:1385–1394. doi:10.4161/cc.24477.
Raabe, C.A., T.-H. Tang, J. Brosius, and T.S. Rozhdestvensky. 2014. Biases in
small RNA deep sequencing data. Nucleic Acids Res. 42:1414–1426.
doi:10.1093/nar/gkt1021.
Record, M. 2013. Exosome-like nanoparticles from food: Protective nanoshuttles
for bioactive cargo. Mol. Ther. 21:1294–1296. doi:10.1038/mt.2013.130.
Saito, Y., T. Nakaoka, and H. Saito. 2015. microRNA-34a as a Therapeutic Agent
against Human Cancer. J. Clin. Med. 4:1951–1959. doi:10.3390/jcm4111951.
Siegel, R.L., K.D. Miller, and A. Jemal. 2018. Cancer statistics, 2018. CA. Cancer
J. Clin. 68:7–30. doi:10.3322/caac.21442.
Slabáková, E., Z. Culig, J. Remšík, and K. Souček. 2017. Alternative mechanisms
of

MIR-34a

regulation

in

cancer.

Cell

Death

Dis.

8:1–10.

doi:10.1038/cddis.2017.495.
Song, L., M.J. Axtell, and N. V. Fedoroff. 2010. RNA Secondary Structural
Determinants of miRNA Precursor Processing in Arabidopsis. Curr. Biol.
20:37–41. doi:10.1016/j.cub.2009.10.076.
Takaoka, Y., Y. Shimizu, H. Hasegawa, Y. Ouchi, S. Qiao, M. Nagahara, M.
Ichihara, J.D. Lee, K. Adachi, M. Hamaguchi, and T. Iwamoto. 2012. Forced
expression of miR-143 represses ERK5/c-Myc and p68/p72 signaling in

66

concert with miR-145 in gut tumors of Apcmin mice. PLoS One. 7.
doi:10.1371/journal.pone.0042137.
Wang, B., X. Zhuang, Z. Deng, H. Jiang, J. Mu, Q. Wang, X. Xiang, H. Guo, L.
Zhang, G. Dryden, J. Yan, D. Miller, and H. Zhang. 2014. Targeted Drug
Delivery to Intestinal Macrophages by Bioactive Nanovesicles Released from
Grapefruit. 22:522–534. doi:10.1038/mt.2013.190.
Wang, G., L. Jacquet, E. Karamariti, and Q. Xu. 2015. Origin and differentiation of
vascular

smooth

muscle

cells.

J.

Physiol.

593:3013–3030.

doi:10.1113/JP270033.
Wang, Q., X. Zhuang, J. Mu, Z. Deng, H. Jiang, L. Zhang, X. Xiang, B. Wang, J.
Yan, D. Miller, and H. Zhang. 2013. Delivery of therapeutic agents by
nanoparticles made of grapefruit-derived lipids. doi:10.1038/ncomms2886.
Weng, W., J. Feng, H. Qin, Y. Ma, and A. Goel. 2015. An update on miRNAs as
biological and clinical determinants in colorectal cancer: a bench-to-bedside
approach. Future Oncol. 11:1791–808. doi:10.2217/fon.15.83.
Werner, S., H. Wollmann, K. Schneeberger, and D. Weigel. 2010. Structure
Determinants for Accurate Processing of miR172a in Arabidopsis thaliana.
Curr. Biol. 20:42–48. doi:10.1016/j.cub.2009.10.073.
Witwer, K.W., and K.D. Hirschi. 2014. Transfer and functional consequences of
dietary microRNAs in vertebrates: Concepts in search of corroboration.
BioEssays. 36:394–406. doi:10.1002/bies.201300150.
Xu, B., J. Cao, J. Zhang, S. Jia, S. Wu, K. Mo, G. Wei, L. Liang, X. Miao, A. Bekker,
and Y.-X. Tao. 2017. Role of MicroRNA-143 in Nerve Injury-Induced

67

Upregulation of Dnmt3a Expression in Primary Sensory Neurons. Front. Mol.
Neurosci. 10:1–13. doi:10.3389/fnmol.2017.00350.
Yan, X., X. Chen, H. Liang, T. Deng, W. Chen, S. Zhang, M. Liu, X. Gao, Y. Liu,
C. Zhao, X. Wang, N. Wang, J. Li, R. Liu, K. Zen, C.Y. Zhang, B. Liu, and Y.
Ba. 2014. MiR-143 and miR-145 synergistically regulate ERBB3 to suppress
cell proliferation and invasion in breast cancer. Mol. Cancer. 13:1–14.
doi:10.1186/1476-4598-13-220.
Yang, J., L.M. Farmer, A.A.A. Agyekum, and K.D. Hirschi. 2015. Detection of
dietary plant-based small RNAs in animals. Cell Res. 25:517–20.
doi:10.1038/cr.2015.26.
Yang, J., T. Hotz, L. Broadnax, M. Yarmarkovich, I. Elbaz-Younes, K.D. Hirschi, Z.
Zhou, L. Zhang, S. Mlotshwa, K.D. Hirschi, G.J. Pruss, V. Vance, J.W. Snow,
A.E. Hale, S.K. Isaacs, A.L. Baggish, S.Y. Chan, K.W. Witwer, M.A.
McAlexander, S.E. Queen, R.J. Adams, B. Dickinson, J. Yang, L.M. Farmer,
A.A.A. Agyekum, K.D. Hirschi, J. Yang, L.M. Farmer, A.A.A. Agyekum, I.
Elbaz-Younes, K.D. Hirschi, J. Yang, K.D. Hirschi, L.M. Farmer, A. Etheridge,
C.P. Gomes, R.W. Pereira, D. Galas, K. Wang, H. Valadi, A. Zampetaki, P.
Willeit, I. Drozdov, S. Kiechl, M. Mayr, J.D. Arroyo, S. Ju, J. Mu, M. Minekus,
S.R. Baier, C. Nguyen, F. Xie, J.R. Wood, J. Zempleni, J. Zempleni, S.R.
Baier, K.D. Hirschi, A. Philip, V.A. Ferro, R.J. Tate, K.W. Witwer, K.D. Hirschi,
X. Chen, and Y. Wang. 2016. Anomalous uptake and circulatory
characteristics of the plant-based small RNA MIR2911. Sci. Rep. 6:26834.
doi:10.1038/srep26834.

68

Zauber, A.G. 2015. The Impact of Screening on Colorectal Cancer Mortality and
Incidence: Has It Really Made a Difference? Dig. Dis. Sci. 60:681–691.
doi:10.1007/s10620-015-3600-5.
Zhang, L., D. Hou, X. Chen, D. Li, L. Zhu, Y. Zhang, J. Li, Z. Bian, X. Liang, X. Cai,
Y. Yin, C. Wang, T. Zhang, D. Zhu, D. Zhang, J. Xu, Q. Chen, Y. Ba, J. Liu,
Q. Wang, J. Chen, J. Wang, M. Wang, Q. Zhang, J. Zhang, K. Zen, and C.-Y.
Zhang. 2012. Exogenous plant MIR168a specifically targets mammalian
LDLRAP1: evidence of cross-kingdom regulation by microRNA. Cell Res.
22:107–26. doi:10.1038/cr.2011.158.
Zhang, M., E. Viennois, C. Xu, and D. Merlin. 2016. Plant derived edible
nanoparticles as a new therapeutic approach against diseases. Tissue
Barriers. 4:1–9. doi:10.1080/21688370.2015.1134415.
Zhang, X., S. Liu, T. Hu, S. Liu, Y. He, and S. Sun. 2009. Up-regulated microRNA143 transcribed by nuclear factor kappa B enhances hepatocarcinoma
metastasis by repressing fibronectin expression. Hepatology. 50:490–499.
doi:10.1002/hep.23008.
Zhou, Z., X. Li, J. Liu, L. Dong, Q. Chen, J. Liu, H. Kong, Q. Zhang, X. Qi, D. Hou,
L. Zhang, G. Zhang, Y. Liu, Y. Zhang, J. Li, J. Wang, X. Chen, H. Wang, J.
Zhang, H. Chen, K. Zen, and C.-Y. Zhang. 2014. Honeysuckle-encoded
atypical microRNA2911 directly targets influenza A viruses. Cell Res. 25:39–
49. doi:10.1038/cr.2014.130.

69

Zhuang, X., Z. Deng, J. Mu, L. Zhang, J. Yan, D. Miller, W. Feng, C.J. Mcclain,
and H. Zhang. 2015. Ginger-derived nanoparticles protect against alcoholinduced liver damage. 1:1–18.

70

